The subgroup analyses in this study furtherrevealed that SGLT-2 inhibitors are the optimal choice for increasing LVEF in HFpatients with increased or decreased ejection fraction or in HF patients withcomorbid T2DM. Here, SLC5A2 is linked to hydrops fetalis.